Payment overview · 2025
General Payments
$546.41
30 reported records · 12 companies
Healthcare provider profile · identity verified
Joel T Johns, MD
Allopathic & Osteopathic Physicians|Internal Medicine · CULLMAN, AL · NPI 1043209703
Verified facts
What the public records show
CMS Open Payments records show Joel T Johns, MD received $546.41 in general payments during 2025 across 30 reported records.
Novo Nordisk Inc accounted for 25.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Mounjaro, Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 166 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $140.56 | 25.7% | 7 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $100.82 | 18.4% | 6 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $74.46 | 13.6% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $48.17 | 8.8% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $38.59 | 7.1% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $33.19 | 6.1% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $23.47 | 4.3% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $21.89 | 4.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $19.97 | 3.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.70 | 2.9% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.43 | 2.8% | 1 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $14.16 | 2.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $546.41 | 30 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $120.05 | 6 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $100.82 | 6 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $100.82 | 6 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $79.88 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $48.17 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $38.59 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $37.61 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $36.85 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $33.19 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $23.47 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $21.89 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $21.89 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $20.51 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $19.97 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $19.97 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.70 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $15.43 | 1 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $14.16 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 166 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 69 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 56 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 57 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 66 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
69 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
66 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
56 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
57 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
166 | 28 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Omeprazole | Omeprazole | 495 | 147 |
| Atorvastatin Calcium | Atorvastatin Calcium | 442 | 132 |
| Montelukast Sodium | Montelukast Sodium | 390 | 147 |
| Levothyroxine Sodium | Levothyroxine Sodium | 381 | 100 |
| Losartan Potassium | Losartan Potassium | 375 | 112 |
| Amlodipine Besylate | Amlodipine Besylate | 352 | 101 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 277 | 44 |
| Lisinopril | Lisinopril | 276 | 80 |
| Tramadol Hcl | Tramadol Hcl | 267 | 50 |
| Pantoprazole Sodium | Pantoprazole Sodium | 261 | 82 |
| Gabapentin | Gabapentin | 224 | 64 |
| Furosemide | Furosemide | 219 | 64 |
| Meloxicam | Meloxicam | 213 | 70 |
| Fluticasone Propionate | Fluticasone Propionate | 197 | 97 |
| Simvastatin | Simvastatin | 195 | 55 |
| Metformin Hcl | Metformin Hcl | 193 | 56 |
| Carvedilol | Carvedilol | 190 | 55 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 184 | 55 |
| Metoprolol Succinate | Metoprolol Succinate | 175 | 52 |
| Hydrochlorothiazide | Hydrochlorothiazide | 173 | 57 |
| Tamsulosin Hcl | Tamsulosin Hcl | 173 | 56 |
| Pravastatin Sodium | Pravastatin Sodium | 171 | 50 |
| Eliquis | Apixaban | 166 | 28 |
| Prednisone | Prednisone | 155 | 86 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 144 | 60 |
| Trazodone Hcl | Trazodone Hcl | 141 | 37 |
| Famotidine | Famotidine | 137 | 54 |
| Potassium Chloride | Potassium Chloride | 130 | 42 |
| Alprazolam | Alprazolam | 126 | 16 |
| Ezetimibe | Ezetimibe | 117 | 37 |
| Escitalopram Oxalate | Escitalopram Oxalate | 115 | 35 |
| Clopidogrel | Clopidogrel Bisulfate | 113 | 32 |
| Metoprolol Tartrate | Metoprolol Tartrate | 112 | 34 |
| Allopurinol | Allopurinol | 110 | 33 |
| Lorazepam | Lorazepam | 109 | 16 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 109 | 13 |
| Glimepiride | Glimepiride | 106 | 31 |
| Sertraline Hcl | Sertraline Hcl | 104 | 34 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 95 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 88 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 87 | 23 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 85 | 24 |
| Metformin Hcl Er | Metformin Hcl | 85 | 21 |
| Clonazepam | Clonazepam | 84 | 16 |
| Spironolactone | Spironolactone | 75 | 23 |
| Azelastine Hcl | Azelastine Hcl | 74 | 49 |
| Ropinirole Hcl | Ropinirole Hcl | 73 | 20 |
| Farxiga | Dapagliflozin Propanediol | 69 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 67 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 66 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 63 | 19 |
| Pregabalin | Pregabalin | 63 | 11 |
| Donepezil Hcl | Donepezil Hcl | 62 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 60 | 12 |
| Baclofen | Baclofen | 59 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 59 | 17 |
| Ozempic | Semaglutide | 57 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 57 | 11 |
| Mounjaro | Tirzepatide | 56 | suppressed |
| Temazepam | Temazepam | 56 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 55 | 45 |
| Buspirone Hcl | Buspirone Hcl | 53 | 15 |
| Methocarbamol | Methocarbamol | 53 | 22 |
| Repatha Sureclick | Evolocumab | 53 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 50 | 23 |
| Tizanidine Hcl | Tizanidine Hcl | 49 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 48 | 38 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 45 | suppressed |
| Finasteride | Finasteride | 44 | 15 |
| Atenolol | Atenolol | 43 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 43 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 43 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 41 | 15 |
| Humalog Kwikpen U-100 | Insulin Lispro | 41 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 41 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 39 | 12 |
| Trulicity | Dulaglutide | 39 | suppressed |
| Cephalexin | Cephalexin | 38 | suppressed |
| Myrbetriq | Mirabegron | 37 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 36 | 11 |
| Fluconazole | Fluconazole | 36 | 20 |
| Jardiance | Empagliflozin | 36 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 35 | suppressed |
| Aripiprazole | Aripiprazole | 35 | suppressed |
| Telmisartan | Telmisartan | 35 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 34 | 12 |
| Febuxostat | Febuxostat | 33 | suppressed |
| Ramipril | Ramipril | 33 | suppressed |
| Xarelto | Rivaroxaban | 33 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 32 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 32 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 31 | suppressed |
| Bupropion Xl | Bupropion Hcl | 31 | suppressed |
| Celecoxib | Celecoxib | 31 | 11 |
| Enalapril Maleate | Enalapril Maleate | 31 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 30 | 26 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 30 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 30 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 29 | suppressed |
| Estradiol | Estradiol | 29 | 12 |
| Januvia | Sitagliptin Phosphate | 29 | suppressed |
| Ranolazine Er | Ranolazine | 29 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 29 | suppressed |
| Mupirocin | Mupirocin | 28 | 14 |
| Valsartan | Valsartan | 28 | suppressed |
| Mirtazapine | Mirtazapine | 27 | suppressed |
| Armour Thyroid | Thyroid,pork | 26 | suppressed |
| Azithromycin | Azithromycin | 26 | 20 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 26 | suppressed |
| Fenofibrate | Fenofibrate | 26 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 26 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Torsemide | Torsemide | 25 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 25 | suppressed |
| Glipizide | Glipizide | 24 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 21 |
| Entresto | Sacubitril/Valsartan | 23 | suppressed |
| Memantine Hcl | Memantine Hcl | 22 | suppressed |
| Nitroglycerin | Nitroglycerin | 21 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 20 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 20 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 20 | suppressed |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 18 | suppressed |
| Nystatin | Nystatin | 18 | 12 |
| Oxycodone Hcl | Oxycodone Hcl | 18 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 18 | suppressed |
| Topiramate | Topiramate | 18 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Etodolac | Etodolac | 17 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 17 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 17 | suppressed |
| Butalbital-Aspirin-Caffeine | Butalbital/Aspirin/Caffeine | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Linzess | Linaclotide | 15 | suppressed |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 15 | suppressed |
| Belsomra | Suvorexant | 14 | suppressed |
| Diazepam | Diazepam | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Rivastigmine | Rivastigmine | 14 | suppressed |
| Synthroid | Levothyroxine Sodium | 14 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Cefdinir | Cefdinir | 12 | 11 |
| Digoxin | Digoxin | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 12 | suppressed |
| Fluocinonide | Fluocinonide | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Multaq | Dronedarone Hcl | 12 | suppressed |
| Novolog | Insulin Aspart | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Minoxidil | Minoxidil | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
| Trandolapril | Trandolapril | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $546.41 · 30 records | Novo Nordisk Inc | AREXVY, BREZTRI, Dexcom G6 Transmitter, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, Kerendia, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, REPATHA, Rybelsus, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, VOQUEZNA, Wegovy, ZTLido | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error